文献速递甲状腺疾病

分化型甲状腺癌术后未行放射性碘治疗时血清甲状腺球蛋白测定的系统评价

Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review.
PubMed 文献 · Thyroid · 2022-05-10

系统评价评估分化型甲状腺癌患者部分甲状腺切除术后或全/近全甲状腺切除术后未行放射性碘治疗时血清甲状腺球蛋白(Tg)测定的诊断准确性。共纳入37项研究,结果显示部分甲状腺切除术后Tg测定对复发或转移诊断不准确或估计不精确;全/近全切除术后未行放射性碘治疗时证据有限,但Tg水平通常稳定且低;放射性碘治疗前Tg cutoff 1-2.5 ng/mL可能识别持续或转移病变低风险患者,但所有场景证据质量极低,需进一步研究。

要点

  • 部分甲状腺切除术后Tg测定对复发或转移诊断不准确或估计不精确。
  • 全/近全切除术后未行放射性碘治疗时证据有限,Tg水平通常稳定且低。
  • 放射性碘治疗前Tg cutoff 1-2.5 ng/mL可能识别持续或转移病变低风险患者。

核心结论

  • 非常有限的证据提示部分甲状腺切除术后Tg测定对识别复发或转移病变效用低。
  • 全/近全甲状腺切除术后,cutoff 1-2.5 ng/mL的Tg水平可能识别持续或转移病变低风险患者。
  • 需要额外研究明确Tg测定在这些情况下的作用、最佳Tg阈值和适当测量间隔。

研究设计与样本

  • 系统评价检索Ovid MEDLINE、Embase和Cochrane Central(2021年10月),纳入部分甲状腺切除术后或全/近全甲状腺切除术后未行或行放射性碘治疗前Tg测定的研究。
  • 共纳入37项研究:4项(N=561)评估部分甲状腺切除术后Tg测定;5项(N=751)评估全/近全甲状腺切除术后未行放射性碘治疗时Tg测定;28项(N=7618)评估全或近全甲状腺切除术后放射性碘治疗前Tg测定。
  • 进行质量评估,证据定性综合。

主要发现

  • 部分甲状腺切除术后,Tg测定对诊断复发或转移不准确,或估计不精确。
  • 全/近全甲状腺切除术后未行放射性碘治疗时,证据有限(复发或转移率非常低的研究少),但提示Tg水平通常稳定且低。
  • 放射性碘治疗前Tg测定对转移病变或持续病变的诊断准确性不一,cutoff >1至2.5 ng/mL时灵敏度似高但特异度低。
  • 放射性碘治疗前Tg测定的适用性对未行放射性碘治疗患者不确定,因选择放射性碘治疗的患者可能代表更高风险组。
  • 所有场景证据质量极低;所有研究均有方法学局限性,Tg阈值、患者人群、评估结局等因素存在变异。

关键数值与推荐

  • 放射性碘治疗前Tg cutoff >1至2.5 ng/mL时灵敏度似高但特异度低。
  • 全/近全甲状腺切除术后Tg cutoff 1-2.5 ng/mL可能识别持续或转移病变低风险患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有场景证据质量极低。
  • 所有研究均有方法学局限性。
  • Tg阈值、患者人群、评估结局和其他因素存在变异。
  • 全/近全甲状腺切除术后未行放射性碘治疗时证据有限,因复发或转移率非常低的研究少。
  • 放射性碘治疗前Tg测定的适用性对未行放射性碘治疗患者不确定,因选择放射性碘治疗的患者可能代表更高风险组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The utility of serum thyroglobulin (Tg) measurement following partial thyroidectomy or total/near-total thyroidectomy without radioactive iodine (RAI) for differentiated thyroid cancer is unclear. This systematic review examines the diagnostic accuracy of serum Tg measurement for persistent, recurrent, and/or metastatic cancer in these situations. Methods: Ovid MEDLINE, Embase, and Cochrane Central were searched in October 2021 for studies on Tg measurement following partial thyroidectomy or total/near-total thyroidectomy without or before RAI. Quality assessment was performed, and evidence was synthesized qualitatively. Results: Thirty-seven studies met inclusion criteria. Four studies (N = 561) evaluated serum Tg measurement following partial thyroidectomy, five studies (N = 751) evaluated Tg measurement following total/near-total thyroidectomy without RAI, and 28 studies (N = 7618) evaluated Tg measurement following total or near-total thyroidectomy before RAI administration. Following partial thyroidectomy, Tg measurement was not accurate for diagnosing recurrence or metastasis, or estimates were imprecise. Following total/near-total thyroidectomy without RAI, evidence was limited due to few studies with very low rates of recurrence or metastasis, but indicated that Tg levels were usually stable and low. For Tg measurements before RAI administration, diagnostic accuracy for metastatic disease or persistence varied, although sensitivity appeared high (but specificity low) at a cutoff of >1 to 2.5 ng/mL. However, applicability to patients who do not undergo RAI is uncertain because patients selected for RAI are likely to represent a higher risk group. The evidence was very low quality for all scenarios. All studies had methodological limitations, and there was variability in the Tg thresholds evaluated, patient populations, outcomes assessed, and other factors. Conclusions: Very limited evidence suggests low utility of Tg measurement for identifying recurrent or metastatic disease following partial thyroidectomy. Following total/near-total thyroidectomy, Tg levels using a cutoff of 1-2.5 ng/mL might identify patients at low risk for persistent or metastatic disease. Additional research is needed to clarify the role of Tg measurement in these settings, determine optimal Tg thresholds, and determine appropriate measurement intervals.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Chou R, Dana T, Brent GA, et al. Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review. Thyroid. 2022. PMID: 35412871. doi:10.1089/thy.2021.0666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。